FDA Inspection 1259338 — Ursapharm Arzneimittel GmbH
The FDA completed an inspection of Ursapharm Arzneimittel GmbH on Oct 31, 2024 in Saarbrucken. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Oct 31, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Saarbrucken (Germany)
Additional details
Mutual Recognition Agreement (MRA)